Stocktoria
Inhibikase Therapeutics, Inc. IKT
Inhibikase Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $260,501 | $123,440 | $3.1M | $698,468 |
| R&D expense | $29.8M | $17.2M | $13.6M | $12.0M | $11.4M | $893,802 |
| SG&A expense | $23.6M | $11.4M | $6.7M | $6.2M | $6.5M | $2.6M |
| Operating income | -$52.0M | -$28.6M | -$20.1M | -$18.1M | -$14.8M | -$2.8M |
| Interest expense | — | — | — | — | $19,923 | $29,402 |
| Income tax | $0 | $0 | — | — | — | — |
| Net income | -$48.3M | -$27.5M | -$19.0M | -$18.1M | -$14.8M | -$2.8M |
| EPS (diluted) | $-0.49 | $-1.16 | $-3.16 | $-4.28 | $-0.81 | — |
| Operating cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.4M | -$14.3M | -$1.1M |
| Free cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.6M | -$14.3M | — |
| Cash & equivalents | $178.8M | $97.5M | $9.2M | $7.2M | $40.8M | — |
| Total assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M | $14.8M |
| Total liabilities | $8.3M | $3.7M | $3.5M | $3.9M | $4.1M | $5.0M |
| Shareholders' equity | $172.9M | $94.9M | $11.0M | $21.0M | $38.4M | $9.8M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | — | -100.0% | +111.0% | -96.0% | +343.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.